Skip to main
CME

CME Group (CME) Stock Forecast & Price Target

CME Group (CME) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 33%
Hold 33%
Sell 8%
Strong Sell 0%

Bulls say

CME Group reported total revenue of $1,649 million, reflecting an 8.1% year-over-year increase, attributed to strong demand in its Market Data segment, which experienced a growth of 14.5% in the quarter. The company has demonstrated robust free cash flow generation, enabling it to increase quarterly dividend payments consistently for over 14 years, highlighting its financial stability and commitment to returning capital to shareholders. Additionally, CME has successfully increased its average daily volume (ADV) at a compound annual growth rate of over 7% from FY16 through FY24, indicating effective product innovation and heightened customer demand in a favorable market environment.

Bears say

CME Group's financial outlook is negatively impacted by anticipated declines in interest rate futures trading volume due to a projected rate-cutting cycle, with expectations for total revenue growth of approximately 5.4% year-over-year to around $6,872 million, falling short of the consensus estimate of 6% growth to about $6,911 million. Furthermore, heightened competitive threats from entities like FMX contribute to pricing pressures, limiting near-term margin upside for the company. The management also highlighted challenges in separating Google-related expenses from baseline technology spending, indicating potential future cost management complexities.

CME Group (CME) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CME Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CME Group (CME) Forecast

Analysts have given CME Group (CME) a Buy based on their latest research and market trends.

According to 12 analysts, CME Group (CME) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $310.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $310.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CME Group (CME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.